250 related articles for article (PubMed ID: 33924134)
21. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
R HC; Kumar S U; R G; Naayanan PJ; Sathiyarajeswaren P; Devi MSS; K SS; Doss C GP
J Cell Biochem; 2023 Feb; 124(2):188-204. PubMed ID: 36563059
[TBL] [Abstract][Full Text] [Related]
22. Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.
Yoon S; Kim M; Hong YS; Kim HS; Kim ST; Kim J; Yun H; Yoo C; Ahn HK; Kim HS; Lee IH; Kim IH; Park I; Jeong JH; Cheon J; Kim JW; Yun J; Lim SM; Cha Y; Jang SJ; Zang DY; Kim TW; Kang JH; Kim JH
Cancer Res Treat; 2022 Jan; 54(1):1-9. PubMed ID: 34902959
[TBL] [Abstract][Full Text] [Related]
23. Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.
Bernhardt EB; Chamberlin MD; Gorlov IP; de Abreu FB; Bloch KJ; Peterson JD; Tsongalis GJ; Shirai K; Dragnev KH; Miller TW; Tafe LJ
Pract Lab Med; 2020 Aug; 21():e00174. PubMed ID: 32613070
[TBL] [Abstract][Full Text] [Related]
24. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
Pezo RC; Chen TW; Berman HK; Mulligan AM; Razak AA; Siu LL; Cescon DW; Amir E; Elser C; Warr DG; Sridhar SS; Yu C; Wang L; Stockley TL; Kamel-Reid S; Bedard PL
Breast Cancer Res Treat; 2018 Feb; 168(1):159-168. PubMed ID: 29177603
[TBL] [Abstract][Full Text] [Related]
25. Implementation of a molecular tumor board at a regional level to improve access to targeted therapy.
Bourien H; Lespagnol A; Campillo-Gimenez B; Felten-Vinot I; Metges JP; Corre R; Lesimple T; le Marechal C; Boussemart L; Kammerer-Jacquet SF; le Gall E; Denoual F; de Tayrac M; Galibert MD; Mosser J; Edeline J
Int J Clin Oncol; 2020 Jul; 25(7):1234-1241. PubMed ID: 32215806
[TBL] [Abstract][Full Text] [Related]
26. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Bayle A; Belcaid L; Aldea M; Vasseur D; Peyraud F; Nicotra C; Geraud A; Sakkal M; Seknazi L; Cerbone L; Blanc-Durand F; Hadoux J; Mosele F; Tagliamento M; Bernard-Tessier A; Verret B; Smolenschi C; Clodion R; Auger N; Romano PM; Gazzah A; Camus MN; Micol J; Caron O; Hollebecque A; Loriot Y; Besse B; Lacroix L; Rouleau E; Ponce S; Soria JC; Barlesi F; Andre F; Italiano A
Ann Oncol; 2023 Apr; 34(4):389-396. PubMed ID: 36709039
[TBL] [Abstract][Full Text] [Related]
28. Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience.
Louie BH; Kato S; Kim KH; Lim HJ; Lee S; Okamura R; Fanta PT; Kurzrock R
Mol Oncol; 2022 Jul; 16(13):2575-2584. PubMed ID: 35238467
[TBL] [Abstract][Full Text] [Related]
29. Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study.
Powell SF; Dib EG; Bleeker JS; Keppen MD; Mazurczak M; Hack KM; Gitau MM; Steen PD; Terstriep SA; Reynolds J; Landsverk ML; Chan CH; Nelson ME; Thompson PA; Ellison C; Black LJ; Ford JM; Chung JH; Anhorn R; Gaba AG
JCO Precis Oncol; 2018 Nov; 2():1-12. PubMed ID: 35135120
[TBL] [Abstract][Full Text] [Related]
30. The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours.
El Helali A; Lam TC; Ko EY; Shih DJH; Chan CK; Wong CHL; Wong JWH; Cheung LWT; Lau JKS; Liu APY; Chan ASY; Loong HH; Lam STS; Chan GC; Lee VHF; Yuen KK; Ng WT; Lee AWM; Ma ESK
Lancet Reg Health West Pac; 2023 Jul; 36():100775. PubMed ID: 37547050
[TBL] [Abstract][Full Text] [Related]
31. Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience.
Hoefflin R; Geißler AL; Fritsch R; Claus R; Wehrle J; Metzger P; Reiser M; Mehmed L; Fauth L; Heiland DH; Erbes T; Stock F; Csanadi A; Miething C; Weddeling B; Meiss F; von Bubnoff D; Dierks C; Ge I; Brass V; Heeg S; Schäfer H; Boeker M; Rawluk J; Botzenhart EM; Kayser G; Hettmer S; Busch H; Peters C; Werner M; Duyster J; Brummer T; Boerries M; Lassmann S; von Bubnoff N
JCO Precis Oncol; 2018; 2():. PubMed ID: 32913998
[TBL] [Abstract][Full Text] [Related]
32. Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
Simarro J; Murria R; Pérez-Simó G; Llop M; Mancheño N; Ramos D; Juan I; Barragán E; Laiz B; Cases E; Ansótegui E; Gómez-Codina J; Aparicio J; Salvador C; Juan Ó; Palanca S
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31426418
[TBL] [Abstract][Full Text] [Related]
33. Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.
Vingiani A; Agnelli L; Duca M; Lorenzini D; Damian S; Proto C; Niger M; Nichetti F; Tamborini E; Perrone F; Piccolo A; Manoukian S; Azzollini J; Brambilla M; Colombo E; Lopez S; Vernieri C; Marra F; Conca E; Busico A; Capone I; Bozzi F; Angelini M; Devecchi A; Salvatori R; De Micheli V; Baggi A; Pasini S; Jommi C; Ladisa V; Apolone G; De Braud F; Pruneri G
JCO Precis Oncol; 2023 Jul; 7():e2300067. PubMed ID: 37487147
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
[TBL] [Abstract][Full Text] [Related]
35. Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?
Rodler S; Jung A; Greif PA; Rühlmann K; Apfelbeck M; Tamalunas A; Kretschmer A; Schulz GB; Szabados B; Stief C; Heinemann V; Westphalen CB; Casuscelli J
Eur J Cancer; 2021 Mar; 146():1-10. PubMed ID: 33535139
[TBL] [Abstract][Full Text] [Related]
36. Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience.
Seet AOL; Tan AC; Tan TJ; Ng MCH; Tai DWM; Lam JYC; Tan GS; Gogna A; Too CW; Tan BS; Takano A; Lim A; Lim TH; Lim ST; Dent RA; Ang MK; Yap YS; Tan IBH; Choo SP; Toh CK; Lim EH; Farid M; Skanderup AJ; Iyer NG; Lim WT; Tan EH; Lim TKH; Tan DSW
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250396
[TBL] [Abstract][Full Text] [Related]
37. Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.
Charo LM; Eskander RN; Sicklick J; Kim KH; Lim HJ; Okamura R; Lee S; Subramanian R; Schwab R; Shatsky R; Plaxe S; Kato S; Kurzrock R
JCO Precis Oncol; 2022 Jan; 6():e2000508. PubMed ID: 35005995
[TBL] [Abstract][Full Text] [Related]
38. Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma.
Blobner J; Dengler L; Blobner S; Eberle C; Weller J; Teske N; Karschnia P; Rühlmann K; Heinrich K; Ziemann F; Greif PA; Jeremias I; Wuerstlein R; Hasselmann K; Dorostkar M; Harter PN; Quach S; Stoecklein V; Albert NL; Niyazi M; Tonn JC; Thon N; Christoph Westphalen B; von Baumgarten L
Neurooncol Adv; 2023; 5(1):vdad060. PubMed ID: 37287694
[TBL] [Abstract][Full Text] [Related]
39. Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network.
Marchetti A; Barbareschi M; Barberis M; Buglioni S; Buttitta F; Fassan M; Fontanini G; Marchiò C; Papotti M; Pruneri G; Scarpa A; Stanta G; Tallini G; Troncone G; Veronese SM; Truini M; Sapino A
Pathologica; 2021 Aug; 113(4):262-271. PubMed ID: 34463674
[TBL] [Abstract][Full Text] [Related]
40. Genomic mutation-driven metastatic breast cancer therapy: a single center experience.
Yuan Y; Yost SE; Yim J; Yuan YC; Solomon NM; Mambetsariev I; Pal S; Frankel P; Salgia R; Neuhausen SL; Mortimer J
Oncotarget; 2017 Apr; 8(16):26414-26423. PubMed ID: 28061482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
